OKLAHOMA Health Care Authority | Serving Oklahomans through SoonerCare

July 6, 2026

RE: Clindesse® and Daytrana® Coverage Changes Effective July 20, 2026

The following changes take effect July 20, 2026. Complete prior authorization (PA) criteria can be found on the OHCA website at www.oklahoma.gov/ohca/pa. Pharmacy PA forms can be found on the OHCA website at www.oklahoma.gov/ohca/rxforms.

Clindesse®

Clindesse® (clindamycin phosphate 2% vaginal cream) will require a PA. The specific PA requirements are listed below and can be found on the OHCA website in the "Dermatologic" therapeutic category.

Clindesse® (Clindamycin Phosphate 2% Vaginal Cream) and Xaciato® (Clindamycin 2% Vaginal Gel) Approval Criteria:

1. An FDA approved diagnosis of bacterial vaginosis; and
2. A patient specific, clinically significant reason why the member cannot use Cleocin® (clindamycin 2% vaginal cream) and Cleocin® vaginal ovules (clindamycin phosphate 2.5g vaginal suppositories), which are available without a prior authorization, must be provided; and
3. Requests for Clindesse® will also require a patient specific, clinically significant reason why the member cannot use Xaciato®.

Daytrana®

Daytrana® (methylphenidate ER patch) will move to Tier-3 of the Attention-Deficit/Hyperactivity Disorder (ADHD) Medications tier chart. Members currently utilizing Daytrana® will be able to continue its use. The ADHD Medications tier chart and specific criteria can be found on the OHCA website in the "Central Nervous System/Behavioral Health" therapeutic category.

Thank you for the services you provide to Oklahomans insured by SoonerCare!

ADDRESS
4345 N. Lincoln Blvd.
Oklahoma City, OK 73105

WEBSITES
oklahoma.gov/ohca
mysoonercare.org

PHONE
Admin: 405-522-7300
Helpline: 800-987-7767